EDMONTON, Oct. 27 /CNW/ - BioMS Medical Corp. (TSX: MS), a leading
developer in the treatment of multiple sclerosis (MS), announced that
following the second meeting of its independent Data Safety Monitoring Board
(DSMB), the Company has received a recommendation to continue its pivotal
phase II/III clinical trial for MBP8298 for the treatment of secondary
progressive multiple sclerosis. This second recommendation by the DSMB members
was based on their recent review of the safety data from patients who have
been dosed in the pivotal phase II/III clinical study.
